Ask AI
ProCE Banner Series

Redefining the Treatment of Squamous Cell Carcinoma of the Anal Canal (SCAC) | The First and Only FDA-Approved PD-1 Inhibitor for Adults with Inoperable Locally Recurrent or Metastatic SCAC

Key Takeaways:

  • Describe the ZYNYZ indications and NCCN Guidelines recommendation
  • Review Squamous Cell Carcinoma of the Anal Canal (SCAC); including epidemiology, incidence, and risk factors
  • Review the clinical efficacy and safety data from the POD1UM-303 trial, including progression free survival (PFS), updated final analysis of overall survival (OS), and the safety profile for ZYNYZ

All Events

Redefining the Treatment of Squamous Cell Carcinoma of the Anal Canal (SCAC) | The First and Only FDA-Approved PD-1 Inhibitor for Adults with Inoperable Locally Recurrent or Metastatic SCAC

Upcoming Events

January

28

2026

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Additional Info

Acknowledgement

Sponsored By

Incyte